Companies: 10,795·Total market cap: $144.5T
Biofrontera Inc.

Biofrontera Inc.

BFRINASDAQHealthcare● Active
$0.93
$-0.00(-0.12%)
Market Cap$11957043
P/E Ratio—
52W High$1.19
52W Low$0.555
ForecastMarket CapPE Ratio

Biofrontera Inc.（BFRI）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

bfri · 股价预测 · 1 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 1 位华尔街分析师

SellBuy

Buy

1 位分析师

共识

评级分布

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
合计: 1 · 买入占比: 100.0%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $0.92

Biofrontera Inc.（BFRI）的分析师共识为 Buy，基于过去 3 个月内 1 位华尔街分析师的评级。BFRI 的 12 个月平均目标价为 $0.00，相对当前价 $0.92 代表 +0.0% 的潜在上行空间。

短期股价预测

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-09$0.97↑ 5.00%

1-day model range: $0.96–$0.98. Peak: $0.98 (+5.00%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$1-36.4%
2028$0-48.0%
2029$0-52.7%
2030$0-54.9%
2031—-55.9%
Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

14%7%79%
2Buy
1Neutral
11Sell
RSI (14)64.1Neutral
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · BFRI · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$0.97SELL
MA 10$0.92SELL
MA 20$0.90BUY
MA 50$0.99SELL
MA 100$0.93SELL
MA 200$0.91BUY
Current $BFRI · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$0.94SELL
EMA 10$0.93SELL
EMA 20$0.94SELL
EMA 50$0.95SELL
EMA 100$0.94SELL
EMA 200$0.92SELL
Current $BFRI · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Benchmark2026-05-19
Maintains
Buy→Speculative Buy
Benchmark2025-05-19
Maintains
Buy→Buy
Benchmark2024-11-15
Maintains
Buy→Buy
Benchmark2024-08-16
Maintains
Buy→Buy
Benchmark2023-08-31
Maintains
Buy→Buy
Benchmark2023-07-05
Maintains
Buy→Buy
Benchmark2023-05-15
Maintains
Buy→Buy

Wall Street analysts have recently issued updated ratings on Biofrontera Inc. (BFRI) stock. Of the recent 7 rating actions, 0 were upgrades and 0 were downgrades. 1 analysts currently cover BFRI.

分析师推荐趋势

Buy ratings1 → 1
Hold ratings0 → 0
Sell ratings0 → 0

BFRI analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$46M

↓ 29.1% YoY

Revenue Next Year

$53M

↑ 15.4% YoY

EPS This Year

$-0.23

EPS Next Year

$0.19

↓ 182.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast BFRI EPS of $-0.23 for the current fiscal year, based on estimates from 1 analysts. The BFRI revenue forecast is $46M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

BFRI 股价预测由两类独立数据源支撑：来自 1 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。BFRI 的共识目标价为 $0.00（+0.0% 上行空间），分析师共识为 Buy。

BFRI 的短期预测（明日）为 $0.97（+5.00%）。 BFRI 对 2027 年的股价预测均值为 $1。 BFRI 对 2030 年的预测区间为 $0–$0。

Biofrontera Inc. 在 NASDAQ 上市，代码 BFRI。BFRI 在 2027 年的整体展望偏积极，在覆盖分析师中约 100% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

BFRI 预测 · 8 个问题

根据 1 位华尔街分析师，BFRI 的 12 个月平均目标价为 $0.00，最高 $0.00、最低 $0.00。若有图表，中位目标价可在上方查看。相对当前价 $0.92，隐含约 +0.0% 的上行空间。

BFRI 目标价BFRI 分析师目标价BFRI 12个月目标价目标价 BFRI

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.